Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
46
LRMR Quote, Financials, Valuation and Earnings
Last price:
$3.81
Seasonality move
:
40.5%
Day range:
$3.66 - $3.80
52-week range:
$1.61 - $6.91
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.28x
Volume:
623.7K
Avg. volume:
1.6M
1-year change:
-38.54%
Market cap:
$316.7M
Revenue:
--
EPS (TTM):
-$1.93
Analysts' Opinion
-
Consensus RatingLarimar Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $16.70, Larimar Therapeutics, Inc. has an estimated upside of 351.35% from its current price of $3.70.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $7.00 representing 100% downside risk from its current price of $3.70.
Fair Value
-
According to the consensus of 10 analysts, Larimar Therapeutics, Inc. has 351.35% upside to fair value with a price target of $16.70 per share.
LRMR vs. S&P 500
-
Over the past 5 trading days, Larimar Therapeutics, Inc. has overperformed the S&P 500 by 4.2% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Larimar Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Larimar Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Larimar Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Larimar Therapeutics, Inc. earnings have been falling on a year-over-year basis for 8 quarters in a row. In the most recent quarter Larimar Therapeutics, Inc. reported earnings per share of -$0.61.
Enterprise value:
145.6M
EV / Invested capital:
1.02x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.03x
EV / Free cash flow:
-1.50x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$340K
Return On Assets:
-71.16%
Net Income Margin (TTM):
--
Return On Equity:
-85.34%
Return On Invested Capital:
-82.74%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$204K | -$322K | -$340K | -$74K | -$88K | |
| Operating Income | -$38M | -$73.8M | -$139.8M | -$18.3M | -$49.5M | |
| EBITDA | -$37.8M | -$73.4M | -$139.4M | -$18.2M | -$49.4M | |
| Diluted EPS | -$0.76 | -$1.15 | -$1.93 | -$0.24 | -$0.61 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $81.3M | $127.1M | $98.5M | $213.3M | $183.2M | |
| Total Assets | $87.9M | $133M | $104M | $219M | $187.4M | |
| Current Liabilities | $10.3M | $9.4M | $6.6M | $16.3M | $45.1M | |
| Total Liabilities | $15.9M | $14.4M | $11.2M | $20.6M | $48.3M | |
| Total Equity | $72.1M | $118.7M | $92.7M | $198.4M | $139M | |
| Total Debt | $6.1M | $4.9M | $4.7M | $4.3M | $3.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$30.8M | -$58.3M | -$96.5M | -$24.5M | -$28.8M | |
| Cash From Investing | -$16.3M | -$107.2M | $85.5M | $27.3M | $33M | |
| Cash From Financing | -$286K | $161.8M | $65.3M | $30K | $65.3M | |
| Free Cash Flow | -$30.8M | -$58.8M | -$96.8M | -$24.6M | -$28.8M | |
LRMR
Sector
Market Cap
$316.7M
$28.5M
Price % of 52-Week High
53.55%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-23.54%
-1.33%
1-Year Price Total Return
-38.54%
-20.32%
Beta (5-Year)
1.051
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$3.53
200-day SMA
Buy
Level
$3.20
Bollinger Bands (100)
Sell
Level
3.45 - 4.31
Chaikin Money Flow
Buy
Level
69.7K
20-day SMA
Buy
Level
$3.50
Relative Strength Index (RSI14)
Buy
Level
51.70
ADX Line
Buy
Level
12.39
Williams %R
Sell
Level
-14.7059
50-day SMA
Sell
Level
$3.90
MACD (12, 26)
Buy
Level
0.03
25-day Aroon Oscillator
Sell
Level
-84
On Balance Volume
Neutral
Level
10M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.7412)
Sell
CA Score
(Annual)
Level (-1.6009)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (4.0176)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.
Stock Forecast FAQ
In the current month, LRMR has received 10 Buy ratings 0 Hold ratings, and 0 Sell ratings. The LRMR average analyst price target in the past 3 months is $16.70.
-
Where Will Larimar Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Larimar Therapeutics, Inc. share price will rise to $16.70 per share over the next 12 months.
-
What Do Analysts Say About Larimar Therapeutics, Inc.?
Analysts are divided on their view about Larimar Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Larimar Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $7.00.
-
What Is Larimar Therapeutics, Inc.'s Price Target?
The price target for Larimar Therapeutics, Inc. over the next 1-year time period is forecast to be $16.70 according to 10 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is LRMR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Larimar Therapeutics, Inc. is a Buy. 10 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of LRMR?
You can purchase shares of Larimar Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Larimar Therapeutics, Inc. shares.
-
What Is The Larimar Therapeutics, Inc. Share Price Today?
Larimar Therapeutics, Inc. was last trading at $3.81 per share. This represents the most recent stock quote for Larimar Therapeutics, Inc.. Yesterday, Larimar Therapeutics, Inc. closed at $3.70 per share.
-
How To Buy Larimar Therapeutics, Inc. Stock Online?
In order to purchase Larimar Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get LRMR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
LRMR
Sector
P/E ratio
--
23.75x
PEG ratio
-0.03x
-0.01x
P/B ratio
2.28x
1.83x
Price / LTM sales
--
1.60x
Growth Metrics
LRMR
Sector
Revenue growth
--
4.85%
Earnings growth
-150.8%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.42
-$0.20
Profitability
LRMR
Sector
Profitability FY 2024
-$318K
$3.6M
Return on invested capital
-82.74%
-30.98%
Return on assets
-71.16%
-27.62%
Return on equity
-85.34%
-36.69%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Mar
30
Estimated Next Earnings Date
Feb
4
Balance Sheet
LRMR
Sector
Total cash
$175.4M
$27.2M
Short term investments
$150.2M
$25.7M
Total assets
$200.9M
$79.7M
Long term debt
$3.2M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 69.73% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 8.64% over the past day.
Sell
13
PSN alert for Dec 8
Parsons Corp. [PSN] is down 5.99% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
